Sanofi’s development of an oral spin on Humira’s mechanism has hit a setback. | Sanofi’s development of an oral spin on ...

Sanofi is continuing to splash the cash for autoimmune and immunology assets this spring by penning a new deal with ...

On its way to generating sales of $14 billion in just its seventh full year on the market, Sanofi and Regeneron’s Dupixent ...

Approval granted for adults and children 12 years and older who remain symptomatic despite antihistamine treatment ...

Preetika Rana is an award-winning reporter for The Wall Street Journal in San Francisco with experience reporting from six countries. Her articles have shaped business practices, opened government ...

Sanofi is scheduled to report results for the first quarter on Thursday. Here is what you need to know. BUSINESS OPERATING PROFIT FORECAST: The French pharmaceutical company is expected to make 2. ...

Paris: Sanofi has received approval from the US Food and Drug Administration (FDA) for Dupixent (dupilumab) for the treatment ...

April 18 (Reuters) - The U.S. Food and Drug Administration approved the use of Sanofi (SASY.PA), opens new tab and Regeneron's (REGN.O), opens new tab blockbuster drug Dupixent for patients with a ...

M.D., Ph.D., Global Therapeutic Area Head, Immunology and Oncology Development at Sanofi. “This FDA approval provides a new treatment option to help address the underlying drivers of these ...

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the U.S. Food and Drug Administration has approved Dupixent ...